<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257360</url>
  </required_header>
  <id_info>
    <org_study_id>WISP_AG52</org_study_id>
    <secondary_id>2009-016782-28</secondary_id>
    <secondary_id>GMIHO 009/2009</secondary_id>
    <nct_id>NCT01257360</nct_id>
  </id_info>
  <brief_title>Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)</brief_title>
  <acronym>NEO-RIT</acronym>
  <official_title>NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>WiSP Wissenschaftlicher Service Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to obtain evidence that, in patients with RAS wildtype tumors,&#xD;
      a chemotherapy-free combined modality treatment with panitumumab is clearly superior to&#xD;
      radiotherapy alone and achieves a pCR rate comparable to that after radiochemotherapy&#xD;
      including two-drug combinations while reducing the toxicity compared to these two-drug&#xD;
      regimens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathological complete remissions</measure>
    <time_frame>15 weeks (average) after start of treatment (at surgery)</time_frame>
    <description>The rate of pathological complete remissions is determined after tumor resection following neoadjuvant treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI CTCAE</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of surgical morbidity and complications</measure>
    <time_frame>Within four weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pTNM findings in relation to initial cTNM staging</measure>
    <time_frame>At surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regression grading according to Dworak</measure>
    <time_frame>At surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rates (CR/PR/SD/PD) after neoadjuvant treatment</measure>
    <time_frame>Before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative biomarker analyses</measure>
  </secondary_outcome>
  <enrollment type="Actual">59</enrollment>
  <condition>Rectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.</description>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation of the pelvis</intervention_name>
    <description>Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of locally advanced rectal cancer (stage II or III)&#xD;
             localised 0 - 12 cm ab ano as measured by rigid rectoscopy (i.e. lower and middle&#xD;
             third of the rectum)&#xD;
&#xD;
          -  Staging requirements: trans-rectal endoscopic ultrasound (EUS) and magnetic resonance&#xD;
             imaging (MRI)&#xD;
&#xD;
          -  Sufficient representative sample material for RAS analysis&#xD;
&#xD;
          -  Wild-type RAS (determined by an accredited local laboratory, if not available by&#xD;
             pathology of Mannheim university)&#xD;
&#xD;
               -  RAS wild-type tested in&#xD;
&#xD;
                    -  KRAS exon 2 (codons 12/13)&#xD;
&#xD;
                    -  KRAS exon 3 (codons 59/61)&#xD;
&#xD;
                    -  KRAS exon 4 (codons 117/146)&#xD;
&#xD;
                    -  NRAS exon 2 (codons 12/13)&#xD;
&#xD;
                    -  NRAS exon 3 (codons 59/61)&#xD;
&#xD;
                    -  NRAS exon 4 (codons 117/146)&#xD;
&#xD;
          -  Informed consent of the patient&#xD;
&#xD;
          -  Aged at least 18 years&#xD;
&#xD;
          -  WHO Performance Status 0-2&#xD;
&#xD;
          -  Life expectancy of al least 12 weeks&#xD;
&#xD;
          -  Adequate haematological, hepatic, renal and metabolic function parameters:&#xD;
&#xD;
               -  Leukocytes &gt; 3000/mm³&#xD;
&#xD;
               -  ANC ≥ 1500/mm³&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm³&#xD;
&#xD;
               -  Hb &gt; 9 g/dl&#xD;
&#xD;
               -  Creatinine clearance ≥ 50 ml/min and serum creatinine ≤ 1.5 x upper limit of&#xD;
                  normal&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal&#xD;
&#xD;
               -  GOT-GPT ≤ 2.5 x upper limit of normal&#xD;
&#xD;
               -  AP ≤ 5 x upper limit of normal&#xD;
&#xD;
               -  Magnesium ≥ lower limit of normal&#xD;
&#xD;
               -  Calcium ≥ lower limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lower border of the tumor localised more than 12 cm ab ano as measured by rigid&#xD;
             rectoscopy&#xD;
&#xD;
          -  Distant metastases (to be excluded by CT scan of the thorax and abdomen)&#xD;
&#xD;
          -  cT4 tumor (as determined by MRI and/or endorectal ultrasound)&#xD;
&#xD;
          -  Risk of tumor involvement of the circumferential resection margin, according to the&#xD;
             MRI assessment&#xD;
&#xD;
          -  Sphincter sparing is the major reason for choosing the neoadjuvant treatment approach&#xD;
&#xD;
          -  Prior antineoplastic therapy for rectal cancer&#xD;
&#xD;
          -  Prior radiotherapy of the pelvic region&#xD;
&#xD;
          -  Major surgery within the last 4 weeks prior to inclusion&#xD;
&#xD;
          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment&#xD;
&#xD;
          -  Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for 6 months (male or&#xD;
             female) after the end of treatment (adequate: oral contraceptives, intrauterine device&#xD;
             or barrier method in conjunction with spermicidal jelly)&#xD;
&#xD;
          -  Serious concurrent diseases&#xD;
&#xD;
          -  On-treatment participation in a clinical study in the period 30 days prior to&#xD;
             inclusion&#xD;
&#xD;
          -  Clinically significant cardiovascular disease in (incl. myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) ≤ 1 year before enrolment&#xD;
&#xD;
          -  History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except&#xD;
             non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is&#xD;
             continuously disease-free&#xD;
&#xD;
          -  Known allergic reactions on study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Hofheinz, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tagestherapiezentrum am ITM &amp; III. Medizinische Klinik, Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Esslingen Klinik für Onkologie, Gastroenterologie und Allgemeine Innere Medizin</name>
      <address>
        <city>Esslingen</city>
        <zip>73780</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Strahlentherapie und Onkologie, Universitätsklinikum Frankfurt am Main</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH Medizinische Klinik III</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tagestherapiezentrum am ITM &amp; III. Medizinische Klinik, Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper Hospital Medizinische Klinik I</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAS-Wildtype</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

